172@29@17@138!~!172@29@0@53!~!|news|world|british-researchers-to-start-trials-for-inhaled-versions-of-oxford-and-imperial-covid-19-vaccine-candidates-5840901.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to PRO at just Rs.33 per month. Use code SUPERPRO
you are here: HomeNewsWorld
Last Updated : Sep 15, 2020 03:01 PM IST | Source: Moneycontrol.com

British researchers to start trials for inhaled versions of Oxford and Imperial COVID-19 vaccine candidates

By Alistair SmoutLONDON Inhaled versions of COVID-19 vaccine candidates developed by Oxford University and Imperial College will be trialled to se..


British researchers will start trial for inhaled versions of COVID-19 vaccine candidates developed by Oxford University and Imperial College to see if they deliver a localised immune response in the respiratory tract. The researchers believe that flu vaccine shots will work better if delivered by nasal spray.

Currently, the Oxford and Imperial vaccines are both being tested in trials through intramuscular injection.

However, scientists from Imperial said that vaccines delivered via inhalation could potentially deliver a more specialised response.

Close

There was evidence that flu vaccines delivered by nasal spray could protect against and reduce transmission of the disease, said Chris Chiu of Imperial’s Department of Infectious Disease.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"We are keen to explore if this may also be the case for SARS-CoV-2 and whether delivering COVID-19 vaccines to the respiratory tract is safe and produces an effective immune response," he said in a statement.

Trials of the Oxford vaccine, which has been licensed to AstraZeneca, resumed at the weekend after safety watchdogs gave it the go-ahead. Late-stage trials had been paused after the study subject fell in Britain.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

"We have already shown that (Oxford vaccine) ChAdOx1 nCoV-19 (AZD1222) is safe and induces strong immune responses after intramuscular injection," said Sarah Gilbert of the University of Oxford.

"Delivering the vaccine to the respiratory tract instead may be a good approach to inducing immune responses in the best place to enable a rapid response after exposure to airborne virus."

Imperial’s vaccine is also in clinical trials, although at an earlier stage.

The new trials of the vaccines will see volunteers receive aerosolised vaccines through a nebulizer, delivering the vaccine as airborne droplets through a mouthpiece. A total of 30 people will be recruited to the trials.

Previous studies suggest that lower doses might be required than in intramuscular injections to give protection, the Imperial researchers said.

Follow our full coverage on COVID-19 here.
First Published on Sep 15, 2020 12:01 pm
Sections